NewsBenzingaUBS nimmt die Beobachtung von Mineralys Therapeutics mit einer Neutral-Bewertung auf und gibt ein Kursziel von 29 $ bekannt UBS nimmt die Beobachtung von Mineralys Therapeutics mit einer Neutral-Bewertung auf und gibt ein Kursziel von 29 $ bekannt Benzinga 2026.10.12 13:33 (GMT+0) Open on Benzinga Other news Futures Gain After Technology Stocks Rebound - TipRanks.com Jones Trading Maintains Buy on Dynex Cap, Lowers Price Target to $12.5 Here's How Much $100 Invested In Gartner 20 Years Ago Would Be Worth Today Microsoft says AI agents are like insider threats as ‘frontier models can’t be trusted’ Dorchester Minerals Enters Into An Agreement To Acquire Mineral And Royalty Interests; To Buy ~ 4,300 Net Royalty Acres In Williston Basin, North Dakota; Interests To Be Exchanged For 1,250,000 Common Units Of Dorchester Minerals Here's How Much $100 Invested In Fastenal 10 Years Ago Would Be Worth Today
Dorchester Minerals Enters Into An Agreement To Acquire Mineral And Royalty Interests; To Buy ~ 4,300 Net Royalty Acres In Williston Basin, North Dakota; Interests To Be Exchanged For 1,250,000 Common Units Of Dorchester Minerals
